The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism

Current Medical Research and Opinion

Volumn 30, Issue 11, 2014, Pages 2179-2190

  Akwaa, Frank ^a   Spyropoulos, Alex C ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b LENOX HILL HOSPITAL   (United States)

Author keywords

Anticoagulants; Bleeding; Clinical trial; Phase III; Risk assessment; Venous thromboembolism complications

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; HEPARIN; RIVAROXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CANCER PATIENT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EMERGENCY CARE; HUMAN; KIDNEY DISEASE; LONG TERM CARE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HEPARIN; HUMANS; MORPHOLINES; PULMONARY EMBOLISM; THIOPHENES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84908619363     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.951425     Document Type: Review

References (72)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:14-18
2. McRae SJ, Ginsberg JS. Initial treatment of venous thromboembolism. Circulation 2004;110:I3-9
3. Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-Term complications of medical patients with hospital-Acquired venous thromboembolism. Thromb Haemost 2009;102:688-93
4. Cohen AT. Long-Term benefits of preventing venous thromboembolic events. Curr Med Res Opin 2012;28:877-89
5. Prandoni P. Prevention and treatment of venous thromboembolism with lowmolecular-weight heparins: clinical implications of the recent European guidelines. Thromb J 2008;6:13
6. Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:I9-16
7. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30
8. Velmahos GC, Spaniolas K, Tabbara M, et al. Pulmonary embolism and deep venous thrombosis in trauma: are they related?. Arch Surg 2009;144:928-32
9. Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002;99:3102-10
10. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996;93:2212-45
11. Garcia D, Ageno W, Libby E. Update on the diagnosis and management of pulmonary embolism. Br J Haematol 2005;131:301-12
12. Goldhaber SZ, Morrison RB. Cardiology patient pages. Pulmonary embolism and deep vein thrombosis. Circulation 2002;106:1436-8
13. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419S-94S
14. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315
15. Rudd KM, Phillips EL. New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. Thrombosis 2013;2013:973710
16. Key NS, Kasthuri RS. Current treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2010;30:372-5
17. Prandoni P, Carnovali M, Marchiori A. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004;164:1077-83
18. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e24-43S
19. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010;121:1523-32
20. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:160S-98S
21. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29:298-310
22. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350:1795-8
23. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998;129:997-1005
24. Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 2008;168:2131-6
25. Spyropoulos AC. Outpatient-based treatment protocols in the management of venous thromboembolic disease. Am J Manag Care 2000;6:S1034-44
26. Jimé nez D, Aujesky D, Moores L, et al. Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010;170:1383-9
27. Bayer Pharma AG. Xarelto (rivaroxaban) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf [Last accessed 19 June 2014
28. Bristol-Myers Squibb, Pfizer EEIG. Eliquis (apixaban) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/002148/ WC500107728.pdf [Last accessed 19 June 2014
29. Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. 2014. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/ 000829/WC500041059.pdf [Last accessed 19 June 2014
30. Miesbach W, Seifried E. New direct oral anticoagulants - current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012;108:625-32
31. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53
32. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115:15-20
33. van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30: 829-37
34. Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013;110: 732-41
35. Prins M, Bamber L, Cano S, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 1163
36. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
37. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
38. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
39. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
40. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
41. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72
42. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008;28:380-6
43. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004;110:I19-26
44. Kearon C. A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. J Thromb Haemost 2012;10:507-11
45. González-Fajardo JA, Martin-Pedrosa M, Castrodeza J, et al. Effect of the anticoagulant therapy in the incidence of post-Thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. J Vasc Surg 2008;48:953-9
46. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18
47. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708
48. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17-21
49. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50
50. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64
51. Prins MH, Lensing AWA, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21
52. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10:807-14
53. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31: 2189-204
54. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013;11:56-70
55. Martin LK, Bekaii-Saab T. Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?. Thrombosis 2012;2012:758385
56. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53
57. Hull RD, Pineo GF, Brant RF, et al. Long-Term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72
58. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-35
59. Bagaria SJ, Bagaria VB. Strategies for diagnosis and prevention of venous thromboembolism during pregnancy. J Pregnancy 2011;2011:206858
60. Bauersachs RM, Dudenhausen J, Faridi A, et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007;98:1237-45
61. Fonseca AG, DCruz DP. Controversies in the antiphospholipid syndrome: can we ever stop warfarin?. J Autoimmune Dis 2008;5:6
62. Raising awareness of antiphospholipid antibody syndrome. Lancet 2010;375:778
63. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?. Lupus 2010;19:486-91
64. A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. University College London, 2012. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002345-38/GB [Last accessed 3 December 2013
65. Robert-Ebadi H, Righini M. Anticoagulation in the elderly. Pharmaceuticals 2010;3:3543-69
66. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95
67. Kazmi RS, Lwaleed BA. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 2011;72:593-603
68. Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban - An oral, direct Factor Xa inhibitor. Thromb Haemost 2012;108:876-86
69. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124: 1573-9
70. van Ryn J, Litzenburger T, Schurer J. In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 3418
71. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation Factor Xa. Nat Med 2013;19:446-51
72. Hollenbach SJ, Lu G, Tan S, et al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 3414